ARIZ Precision Medicine

Executive Summary

ARIZ Precision Medicine is a preclinical-stage biopharmaceutical company pioneering first-in-class cancer therapies that combine proprietary genetic targeting with a nanotechnology-based drug delivery system. Founded in 2018 and headquartered in Phoenix, Arizona, the company focuses on delivering siRNA payloads specifically to cancer cells to address the root genetic drivers of tumor growth and metastasis. Its platform aims to provide curative treatments by silencing the initial genetic errors that cause cancer, offering a potential paradigm shift in oncology. ARIZ’s approach is distinct in leveraging a targeted drug delivery system (T-DDS) that enhances therapeutic efficacy while minimizing off-target effects, a critical advantage over conventional siRNA therapies that suffer from poor cellular uptake and stability. Currently at the preclinical stage, the company is advancing its lead candidates toward investigational new drug (IND)-enabling studies, with the goal of entering clinical trials within the next 18–24 months. Despite the high-risk nature of early-stage biotech, ARIZ’s innovative platform and precision medicine focus position it to address significant unmet needs in cancer treatment, particularly for genetically defined tumors. The company’s progress will hinge on successful validation of its technology in animal models and eventual human proof-of-concept. With a lean operational structure and a clear strategic vision, ARIZ Precision Medicine represents a compelling opportunity for investors seeking exposure to cutting-edge oncology therapeutics, though significant technical and regulatory hurdles remain. The next 12 months are critical for demonstrating in vivo efficacy and safety, which will determine the trajectory of its pipeline and potential partnerships.

Upcoming Catalysts (preview)

• Q3 2026Presentation of in vivo efficacy data for lead siRNA candidate at a major oncology conference60% success
• H1 2027Completion of IND-enabling toxicology studies and submission of IND application40% success
• Q4 2026Announcement of a strategic partnership or licensing deal for T-DDS platform25% success